Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer J Clinicians. 2023;73:17–48.

Google Scholar 

Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in Incidence of Metastatic Prostate Cancer in the US. JAMA Netw Open. 2022;5:e222246.

Article  PubMed  PubMed Central  Google Scholar 

Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19:395–7.

Article  CAS  PubMed  Google Scholar 

Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.

Article  PubMed  Google Scholar 

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

Article  CAS  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71:151–4.

Article  CAS  PubMed  Google Scholar 

Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, et al. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019;22:420–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shore ND, Laliberté F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. Adv Ther. 2021;38:4520–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27:327–33.

Article  CAS  PubMed  Google Scholar 

Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, et al. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41:2736–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020;78:347–57.

Article  CAS  PubMed  Google Scholar 

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl J Med. 2020;383:2345–57.

Article  CAS  PubMed  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl J Med. 2020;382:2091–102.

Article  PubMed  Google Scholar 

Agarwal N, Azad A, Carles J, Fay AP, Matsubara N, Heinrich D, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:LBA17–LBA.

Article  Google Scholar 

Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975–86.

Article  CAS  PubMed  Google Scholar 

Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34:772–82.

Article  CAS  PubMed  Google Scholar 

Tsai AK, Kagalwalla S, Langer J, Le-Kumar T, Le-Kumar V, Antonarakis ES. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert Opin Biol Ther. 2024;24:51–62.

Article  CAS  PubMed  Google Scholar 

Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, et al. Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA Netw Open. 2024;7:e2423186.

Article  PubMed  PubMed Central  Google Scholar 

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, et al. DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol. 2017;71:417–25.

Article  CAS  PubMed  Google Scholar 

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lukashchuk N, Barnicle A, Adelman CA, Armenia J, Kang J, Barrett JC, et al. Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Front Oncol. 2023;13:1162644.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, et al. Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer. 2022;22:13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14:e1005965.

Article  PubMed  PubMed Central  Google Scholar 

Barata PC, Assayag J, Li B, Siu G, Niyazov A. Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2024;10:975–7.

Article  PubMed  PubMed Central  Google Scholar 

Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023;209:1082–90.

Article  PubMed  Google Scholar 

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021;205:14–21.

Article  PubMed  Google Scholar 

Tung N, Ricker C, Messersmith H, Balmaña J, Domchek S, Stoffel EM, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42:2599–2615.

Article  CAS  PubMed  Google Scholar 

Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, et al. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. JCO Precis Oncol. 2023;7:e2200104.

Article  PubMed  PubMed Central  Google Scholar 

Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, et al. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precis Oncol. 2021;5:1377–86.

Article